Quick Answer
Ovid Therapeutics Inc. reported R&D Expense of $25.58 million for fiscal year 2025.
Ovid Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $25.58M | -30.4% |
| 2024 | $36.77M | +28.6% |
| 2023 | $28.59M | +16.1% |
| 2022 | $24.62M | -47.6% |
| 2021 | $46.94M | -26.0% |
| 2020 | $63.42M | +50.4% |
| 2019 | $42.16M | +24.8% |
| 2018 | $33.79M | -32.4% |
| 2017 | $49.97M | +421.3% |
| 2016 | $9.59M | +45.0% |
| 2015 | $6.61M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.87M | -25.3% | -9.2% |
| June 30, 2025 | $6.46M | -48.6% | -2.9% |
| March 31, 2025 | $6.66M | -36.0% | -15.2% |
| September 30, 2024 | $7.86M | +47.3% | -37.6% |
| June 30, 2024 | $12.58M | +109.7% | +21.0% |
| March 31, 2024 | $10.40M | +57.2% | +95.0% |
| September 30, 2023 | $5.33M | +2.9% | -11.1% |
| June 30, 2023 | $6.00M | -0.8% | -9.3% |
- Ovid Therapeutics Inc. showed a decrease of -30.4% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Ovid Therapeutics Inc.’s r&d expense has grown by 286.9% (from $6.61 million to $25.58 million).
- The most recent figure is from Ovid Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: